FEV
Cardiovascular disease
FEV(1)
FVC
Mortality
Population attributable fraction
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
23
10
2023
revised:
26
03
2024
accepted:
28
03
2024
medline:
27
4
2024
pubmed:
27
4
2024
entrez:
26
4
2024
Statut:
aheadofprint
Résumé
Data is limited on influence of forced expiratory volume in 1 s (FEV Using the UK Biobank cohort, a multivariable Cox regression analysis was conducted on 406,424 individuals to examine the association between FEV Reduced FEV Reduced FEV
Identifiants
pubmed: 38670319
pii: S0954-6111(24)00088-X
doi: 10.1016/j.rmed.2024.107614
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107614Informations de copyright
Copyright © 2024. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest AR has disclosed receiving lecturing fees from AstraZeneca, unrelated to the present project. CJ served on advisory boards for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Orion and Sanofi and received lecturing fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Orion and Sanofi all unrelated to the present project. KL has served on advisory boards for AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and received lecturing fees from AstraZeneca, Boehringer Ingelheim, Chiesi and Novartis all unrelated to this project. JÄ has served on advisory boards for AstraZeneca, Boerhinger Ingelheim, and Astella, and received lecturing fees from Astrazeneca and Novartis, all unrelated to the present project.